De Neuroloog Nummer 3, p. 11
jun 2021, jaargang 28
De Neuroloog Nr. 3, p. 11
jun 2021, jr. 28
Opleiding

NEUROLOGENTOETS 2021 Wat was de moeilijkste vraag?

Begin februari deden 795 neurologen en aios neurologie mee aan de jaarlijkse neurologentoets. Het gemiddeld behaalde cijfer was 7,3, ruim 95 procent haalde een voldoende (≥5,5) en 96 procent van de deelnemende neurologen heeft daarmee acht accreditatie-uren behaald.

Referenties

  1. Bushnell CD, Zimmer LO, Pan W, et al. Persistence with stroke prevention medications 3 months after hospitalization. JAMA neurology. Published online 2010.
  2. Wang Y, Zhao X, Lin J, et al. Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA - Journal of the American Medical Association. 2016;316(1):70-78. doi:10.1001/jama.2016.8662
  3. Pan Y, Chen W, Xu Y, et al. Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack. Circulation. 2017;135(1):21-33. doi:10.1161/CIRCULATIONAHA.116.024913
  4. Meschia JF, Walton RL, Farrugia LP, et al. Efficacy of Clopidogrel for Prevention of Stroke Based on CYP2C19 Allele Status in the POINT Trial. Stroke. 2020;51:2058-2065. doi:10.1161/STROKEAHA.119.028713
  5. Diener HC. The PRoFESS trial: Future impact on secondary stroke prevention. Expert Review of Neurotherapeutics. 2007;7(9):1085-1091. doi:10.1586/14737175.7.9.1085
  6. Johnston SC, Amarenco P, Albers GW, et al. Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. New England Journal of Medicine. 2016;375(1):35-43. doi:10.1056/nejmoa1603060
  7. Cavallari LH, Lee CR, Beitelshees AL, et al. Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions. 2018;11(2):181-191. doi:10.1016/j.jcin.2017.07.022
  8. Zhong Z, Hou J, Zhang Q, et al. Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China. European Journal of Clinical Pharmacology. 2018;74(4):423-431. doi:10.1007/s00228-017-2393-1
  9. KNMG. Farmacogenetica-Update Vanaf Februari 2021.
  10. Startpagina herseninfarct/-bloeding - Richtlijn - Richtlijnendatabase. Accessed January 19, 2021. https://richtlijnendatabase.nl/herseninfarct_en_hersenbloeding
Opleiding

NEUROLOGENTOETS 2021 Wat was de moeilijkste vraag?

Begin februari deden 795 neurologen en aios neurologie mee aan de jaarlijkse neurologentoets. Het gemiddeld behaalde cijfer was 7,3, ruim 95 procent haalde een voldoende (≥5,5) en 96 procent van de deelnemende neurologen heeft daarmee acht accreditatie-uren behaald.

Referenties

  1. Bushnell CD, Zimmer LO, Pan W, et al. Persistence with stroke prevention medications 3 months after hospitalization. JAMA neurology. Published online 2010.
  2. Wang Y, Zhao X, Lin J, et al. Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA - Journal of the American Medical Association. 2016;316(1):70-78. doi:10.1001/jama.2016.8662
  3. Pan Y, Chen W, Xu Y, et al. Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack. Circulation. 2017;135(1):21-33. doi:10.1161/CIRCULATIONAHA.116.024913
  4. Meschia JF, Walton RL, Farrugia LP, et al. Efficacy of Clopidogrel for Prevention of Stroke Based on CYP2C19 Allele Status in the POINT Trial. Stroke. 2020;51:2058-2065. doi:10.1161/STROKEAHA.119.028713
  5. Diener HC. The PRoFESS trial: Future impact on secondary stroke prevention. Expert Review of Neurotherapeutics. 2007;7(9):1085-1091. doi:10.1586/14737175.7.9.1085
  6. Johnston SC, Amarenco P, Albers GW, et al. Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. New England Journal of Medicine. 2016;375(1):35-43. doi:10.1056/nejmoa1603060
  7. Cavallari LH, Lee CR, Beitelshees AL, et al. Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions. 2018;11(2):181-191. doi:10.1016/j.jcin.2017.07.022
  8. Zhong Z, Hou J, Zhang Q, et al. Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China. European Journal of Clinical Pharmacology. 2018;74(4):423-431. doi:10.1007/s00228-017-2393-1
  9. KNMG. Farmacogenetica-Update Vanaf Februari 2021.
  10. Startpagina herseninfarct/-bloeding - Richtlijn - Richtlijnendatabase. Accessed January 19, 2021. https://richtlijnendatabase.nl/herseninfarct_en_hersenbloeding
Over dit artikel
Auteurs
Iris Knottnerus, Henk Kerkhoff
Over de auteurs

Dr. Iris Knottnerus (MST) en dr. Henk Kerkhoff (Albert Schweitzer ziekenhuis en lid van de Toetsingscommissie)

Printdatum
4 juni 2021
E-pubdatum
7 juni 2021
ISSN print
1380-3476
ISSN online
2352-9253
DOI
https://doi.org/10.24078/dng.2021.6.127353


Over dit artikel
Auteurs
Iris Knottnerus, Henk Kerkhoff
Over de auteurs

Dr. Iris Knottnerus (MST) en dr. Henk Kerkhoff (Albert Schweitzer ziekenhuis en lid van de Toetsingscommissie)

Printdatum
4 juni 2021
E-pubdatum
7 juni 2021
ISSN print
1380-3476
ISSN online
2352-9253
DOI
https://doi.org/10.24078/dng.2021.6.127353